Karamisheva V, Ivanov S, Jordanova D, Marinov B, Dimitrov G, Nachev A
Akush Ginekol (Sofiia). 2014;53 Suppl 1:8-12.
The aim of the study is to establish the safety and efficacy of calcium channel blocker- Nifedipin as tocolytic agents. A wide range of tocolytics have been utilized for the management of preterm labor Calcium channel blockers, namely nifedipine, gained popularity as tocolytics due to the oral route of administration, availability of immediate- and slow-release preparations, the low incidence of maternal adverse effects associated with their use, and the fact that they are inexpensive.
88 pregnant women in preterm labor participated in a prospective longitudinal study Inclusion criteria were: gestational age between 24 and 34 weeks gestation; uterine contractions in 10-15 min interval; single pregnancy, lack of contraindications for tocolysis. In all cases the calcium antagonist Nifedipine was used in dosage 4 x 10 mg per os. The clinical response to tocolysis, gestational age at delivery and potential side effects were analyzed.
91 pregnant women participated in the study. Three were excluded because they refused to participate. 88 pregnancies were finally analyzed. In nine of them maternal contractions persisted despite of treatment. The other 79 pregnancies were delayed 48 hours to receive antenatal corticosteroids. From all these 79 pregancies 66 delayed 7 days. The most common adverse effects were tachycardia, hypotonia, headache, dizziness, but they escape soon after the first dose.
Nifedipine is an effective oral tocolytic with few maternal side effects.
本研究的目的是确定钙通道阻滞剂硝苯地平作为宫缩抑制剂的安全性和有效性。多种宫缩抑制剂已被用于早产的治疗。钙通道阻滞剂，即硝苯地平，因其口服给药途径、速释和缓释制剂的可用性、使用时母体不良反应发生率低以及价格低廉等因素，作为宫缩抑制剂而受到欢迎。
88例早产孕妇参与了一项前瞻性纵向研究。纳入标准为：孕龄在24至34周之间；宫缩间隔为10 - 15分钟；单胎妊娠，无宫缩抑制的禁忌证。所有病例均口服使用钙拮抗剂硝苯地平，剂量为4×10毫克。分析了宫缩抑制的临床反应、分娩时的孕龄及潜在副作用。
91例孕妇参与了研究。3例因拒绝参与而被排除。最终分析了88例妊娠情况。其中9例尽管接受了治疗，母体宫缩仍持续。其他79例妊娠被推迟48小时以接受产前皮质类固醇治疗。在这79例妊娠中，66例被推迟了7天。最常见的副作用是心动过速、肌张力减退、头痛、头晕，但在首剂后很快消失。
硝苯地平是一种有效的口服宫缩抑制剂，母体副作用少。
